Cell therapy as a new medical technology in the 21st century has become the consensus of medical community in the world. The US Food and Drug Administration divides cell therapy products into stem cell-derived cell therapy products and mature/ functionally differentiated cell-derived cell therapy products. Cell therapy community in China has not clearly defined these two kinds of cell therapy products. One serious issue is that cell therapy community in China misuses the identification standards of mesenchymal stromal cell established by International Society of Cellular Therapy as the identification standard of mesenchymal stem cell, which has led to wrong policy, regulation and administration of cell therapy from the relevant government ministries, and hinder the development of cell therapy in China. In terms of the long history of clinical cell therapy of neruorestoration, published papers, number of treated patients, treatment outcome and impact in professional field, China is currently in the forefront of the world in the clinical cell therapy of neurorestoration. Only the academic community of cell therapy defines the clear concept of both stem cell therapy products and mature/ functionally differentiated cell therapy products and determines their boundaries, and related government ministries may develop laws and regulations with a clear boundary between two kinds of cell therapy products, which can promote clinical cell therapy innovation in China.